Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Philip Q. Ding"'
Publikováno v:
Cancer Medicine, Vol 13, Iss 13, Pp n/a-n/a (2024)
Abstract Background Lenvatinib (LEN) and atezolizumab + bevacizumab (A + B) have drastically changed the treatment paradigm for advanced hepatocellular carcinoma (HCC). Before these landmark trials, sorafenib (SOR) served as the standard first‐line
Externí odkaz:
https://doaj.org/article/9fffefafa3f9486a9648faba9dbbcc8e
Autor:
Taylor E. Woo, Igor Stukalin, Philip Q. Ding, Siddhartha Goutam, Michael Sander, Benjamin Ewanchuk, Winson Y. Cheung, Daniel Y. C. Heng, Tina Cheng
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 8936-8947 (2023)
Background: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. Methods: A retrospective, multi-center, provincial cohort da
Externí odkaz:
https://doaj.org/article/d3356bccbd954bebb8c1372aca614954
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 8005-8018 (2023)
The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada’s first and only approved oral hypomethylating agent for MDS and CM
Externí odkaz:
https://doaj.org/article/b48668b1455c4f7c8dd47a3180a53e66
Publikováno v:
Current Oncology, Vol 30, Iss 1, Pp 130-144 (2022)
Background: Gastric cancer mortality remains among the highest of all cancers. Trifluridine/tipiracil (FTD/TPI) represents Canada’s first standard-of-care, third-line, systemic therapy for metastatic gastric/gastroesophageal cancer. We characterize
Externí odkaz:
https://doaj.org/article/38608fc2e2a04cfa8fa4ece8e063c171
Autor:
Daniel Breadner, Jonathan M. Loree, Winson Y. Cheung, Meghan Gipson, Suganija Lakkunarajah, Karen E. Mulder, Jennifer L. Spartlin, Shiying Kong, Philip Q. Ding, Sharlene Gill, Stephen A. Welch
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Colorectal cancer remains the second leading cause of cancer death in North America. Fluorouracil and oxaliplatin based adjuvant chemotherapy for resected colon cancer (CC) reduces cancer recurrence, but also causes significant to
Externí odkaz:
https://doaj.org/article/1d997dd7e2c34753b98355ea02900e26
Autor:
Siddhartha Goutam, Igor Stukalin, Benjamin Ewanchuk, Michael Sander, Philip Q. Ding, Daniel E. Meyers, Daniel Heng, Winson Y. Cheung, Tina Cheng
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7695-7704 (2022)
Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of long-term survival remain elus
Externí odkaz:
https://doaj.org/article/1f5f9e1739c3404695cccba5ce955721
Publikováno v:
Cancers, Vol 15, Iss 16, p 4121 (2023)
Surveillance of stage IV colorectal cancer (CRC) after curative-intent metastasectomy can be effective for detecting asymptomatic recurrence. Guidelines for various forms of surveillance exist but are supported by limited evidence. We aimed to determ
Externí odkaz:
https://doaj.org/article/2dcf881781e54d07bd145674c596dad7
Autor:
Rodrigo Rigo, Jordan Doherty, Kim Koczka, Shiying Kong, Philip Q. Ding, Tina Cheng, Winson Y. Cheung, Jose G. Monzon
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3978-3986 (2021)
Immune checkpoint and MAP kinase pathway inhibitors can significantly improve long-term survival for patients with melanoma. There is limited real-world data of these regimens’ effectiveness. We retrospectively analyzed 402 patients with unresectab
Externí odkaz:
https://doaj.org/article/1ed2b878f5f14461985de358d55e844e
Autor:
Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb, Don G. Morris, Winson Y. Cheung, Aliyah Pabani
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 4213-4222 (2021)
The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical practice
Externí odkaz:
https://doaj.org/article/ef1a3db40d2d4a92a300be45448be0e8
Publikováno v:
Cancers, Vol 14, Iss 24, p 6197 (2022)
Background: There are limited published data in the Canadian healthcare system on the use of granulocyte colony-stimulating factor (G-CSF) among patients with breast cancer. This study characterized real-world G-CSF use during the period surrounding
Externí odkaz:
https://doaj.org/article/6a3c7ed8b1cf4e3b9c2914e29fa16c94